<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149149</url>
  </required_header>
  <id_info>
    <org_study_id>05/Q0408/19</org_study_id>
    <nct_id>NCT00149149</nct_id>
  </id_info>
  <brief_title>Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers</brief_title>
  <official_title>Use of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers Taking Non-steroidal Anti-inflammatory Drugs (NSAIDs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wexham GI Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <brief_summary>
    <textblock>
      Zinc carnosine is a food supplement which is available in the health food shops. The
      investigators wish to see if it can reduce intestinal swelling in people who take
      non-steroidal anti-inflammatory (anti-swelling) drugs (NSAIDs).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of zinc carnosine in reducing the gut damage caused by non-steroidal anti-inflammatory drugs</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in dyspepsia score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in faecal calprotectin</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc carnosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-35 years

        Exclusion Criteria:

          -  Conditions known to alter intestinal permeability, eg previous bowel surgery, celiac
             disease

          -  Conditions where NSAIDs are contraindicated, eg asthma, renal failure, heart failure

          -  Diabetes

          -  Any other serious illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Playford, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asif Mahmood, MD</last_name>
    <phone>02083838067</phone>
    <email>asif.mahmood@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asif Mahmood, MD</last_name>
      <phone>02083838067</phone>
      <email>asif.mahmood@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Asif Mahmood, MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raymond Playford, FRCP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <keyword>Reduction in NSAID related gut damage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polaprezinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

